Symbiotic Capital brings together a world-class team of scientists, financiers and entrepreneurs to provide credit partnerships to compelling life science companies around the world
Symbiotic Capital held the final close of its inaugural fund and has already originated hundreds of millions of dollars in credit loans
LOS ANGELOS, August 6, 2024 /PRNewswire/ — Symbiotic Capital (“Symbiotic”), a global life science credit firm, officially unveiled today with more than 600 million dollars in committed and targeted capital for investments and co-investments. Symbiotic Capital is affiliated with Bellco Capital (“Bellco”), the Los Angeles-based investment firm founded by biotechnology entrepreneur Dr. Arie Belldegrun. Symbbiotic will structure and create credit solutions for compelling life science companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology and other healthcare subsectors.
“The life science industry continues to experience unprecedented productivity, innovation and scientific discovery as biotechnology and technology converge,” said Symbiotic co-chairman Dr. Arie Belldegrun. “As the cost of research, development and commercialization of innovative therapies, devices, tools and other products has increased significantly across the sector, credit has become an increasingly important financing tool for established healthcare enterprises. With Symbbiotic Capital , we’ve designed a science-first credit platform to drive those efforts.”
“Over the past three decades, Bellco’s ecosystem has partnered with visionaries across the life sciences to build and invest in compelling enterprises and develop innovation labs and campuses. We are extremely excited to launch Symbiotik Capital and unlocking our ecosystem’s resources, relationships, knowledge and ‘patients’ first mindset for borrowers across the healthcare industry,” said Josh BradleyChief Investment Officer of Bellco and Co-Founder of Symbiotic.
Symbiotic’s integrated scientific team includes Drs. Franz Humer (former chairman and CEO of Roche), Dr. Toby Cosgrove (former president and CEO of the Cleveland Clinic), UCLA researchers Dr. Jim Economou and Dr. Owen Witteleading life science venture investors Amy Schulman AND Helen Kimand veteran life science company builder Joshua Kazam.
“Traditional funding institutions have struggled to meet the growing capital needs of growing healthcare companies due to the complexity of the underlying science and competitive environment,” said Russell Goldsmith, Co-Chairman of Symbiotic and former Chairman and CEO of City National Bank. “With Symbiotic Capital, we have assembled a uniquely qualified, multidisciplinary and experienced team that brings together the best of traditional loan underwriting with deep sector fundamentals and expertise.”
As life science companies finance ongoing research and development, capital expenditures and commercialization activities, debt financing can minimize the capital requirements otherwise needed for such operations and expansions.
“Credit is a more powerful tool when it is provided by a reliable partner who is connected and able to support the entire enterprise of the borrower,” said Himani Bhalla, Chief Investment Officer and Co-Founder of Symbbiotic. “Symbiotic’s offerings build on traditional credit benefits and provide partner-driven relationships for innovative life science companies around the world.”
About Symbiotic Capital (symbcap.com)
Symbbiotic Capital is a life science credit firm that brings together decades of experience in life sciences, finance and entrepreneurship. Our integration into a global life science ecosystem empowers us to provide credit solutions to fuel the growth of established life science companies around the world.
Life Science Credit. For science, by science.
For more information, please visit www.symbcap.com.
About Bellco Capital (bellcocapital.com)
Bellco Capital is an investment firm founded in 2003 by Dr. Rebecka Belldegrun, MD and Arie Belldegrun, MD Over decades, the Bellco ecosystem has incubated and built leading life science companies, invested in transformative science, and developed life science real estate across the globe, generating value creation of immense in the process.
For more information, please visit www.bellcocapital.com.
contacts
Dan Boyle
[email protected]
SOURCE Symbiotic Capital
